METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) TESTING SYSTEMS MARKET ANALYSIS

The global methicillin resistant staphylococcus aureus (MRSA) testing systems market is estimated to be valued at US$ 141.3 million in 2023 and is expected to exhibit a CAGR of 10.8% during the forecast period (2023-2030).

Analysts’ Views on Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market:

Methicillin Resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat to health. The growing prevalence of methicillin resistant staphylococcus aureus infection worldwide is expected to drive growth of the methicillin resistant Staphylococcus aureus (MRSA) testing systems market. The market's expansion relies on various elements, such as the escalating prevalence of staphylococcal infections, the implementation of novel MRSA diagnostic tests, and the enhanced integration of automation and systems in the healthcare sector. While the market demonstrates growth, it also faces obstacles like the scarcity of skilled practitioners. 

Figure 1. Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market Share (%), By Product Type, 2023

To learn more about this report, request sample copy

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market– Drivers

Increasing prevalence of methicillin resistant staphylococcus aureus infection

The increasing prevalence of methicillin resistant staphylococcus aureus infection is expected to drive the global methicillin resistant staphylococcus aureus (MRSA) testing systems market growth over the forecast period. For instance, according to the U.S. Department of Health and Human Services report of March 2021, nearly 320,000 staphylococcus aureus bloodstream infections and 50,000 associated deaths occurred in the U.S. in 2020. After years of slow progress, the rate of decline of MRSA bloodstream infections has slowed, but bloodstream infections caused by methicillin-susceptible staphylococcus aureus in hospitals are increasing day by day in the community.

Products approvals by regulatory bodies

Products approvals by regulatory bodies are expected to accelerate the methicillin resistant staphylococcus aureus (MRSA) testing systems market growth in the forecast period. For instance, in April 2021, Luminex Corporation, a biotechnology company which develops, manufactures, and markets proprietary biological testing technologies in the U.S., announced that the company had received the U.S. Food and Drug Administration (FDA) 510(k) clearance for the ARIES MRSA Assay. The assay is an integrated, real-time, polymerase chain reaction (PCR) based, qualitative, in vitro diagnostic test for the direct detection of methicillin-resistant Staphylococcus aureus (MRSA) DNA from nasal swabs in patients at risk for nasal colonization. Luminex ARIES System is an instrument designed to increase laboratory efficiency, ensure result accuracy, and fit seamlessly into the modern laboratory.

Figure 2. Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market Share (%), By Region, 2023

To learn more about this report, request sample copy

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market- Regional Analysis

Among region, North America is estimated to hold a dominant position in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market over the forecast period. North America is estimated to hold 42.8% of the market share in 2023. North America methicillin resistant staphylococcus aureus (MRSA) testing systems market is expected to witness significant growth in the future, owing to expansion of product portfolio and launch of new products. For instance, in February 2021, Paratek Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company in the U.S., announced the expansion of the company’s commercial promotion of NUZYRA (omadacycline) is indicated for the treatment of adult patients with community-acquired bacterial pneumonia.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market– Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand for drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others faced problems regarding the transportation of  Products from one place to another.

However, the COVID-19 pandemic had positive impact on the global methicillin resistant staphylococcus aureus (MRSA) testing systems market. For instance, an article published in the National Library of Medicine, in August 2020, reported the prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in respiratory cultures and diagnostic performance of MRSA nasal polymerase chain reaction (PCR) in patients hospitalized with coronavirus disease 2019 (COVID-19) pneumonia.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market Segmentation:

The global methicillin resistant staphylococcus aureus (MRSA) testing systems market report is segmented into by product type, by test type, by end user and region.

By Product Type, the market is segmented into instruments and reagents & kits. Out of which, instruments segment is expected to hold a dominant position in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market during the forecast period, owing to technological advancements in the field of methicillin resistant staphylococcus aureus (MRSA) testing systems.

By Test Type, the market is segmented into immunodiagnostic test and molecular diagnostic test. Out of which, Immuno diagnostic test segment is expected to hold a dominant position in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market during the forecast period, owing to increasing prevalence of staphylococcus aureus infection.

By End User, the market is segmented into hospitals, diagnostic laboratories, and academic and research institutes. Out of which, the diagnostic laboratories segment is expected to dominate the market over the forecast period and this is attributed to the prompt treatment can lead to proper recovery.

Among all the segmentations, the product type segment has the potential due to increasing advancements in methicillin resistant staphylococcus aureus (MRSA) testing systems. This is attributed to the accurate detecting of methicillin resistant staphylococcus aureus infection.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market- Cross Sectional Analysis:

Key players are manufacturing new methicillin resistant staphylococcus aureus (MRSA) testing systems with advanced technology in emerging economies, and this is expected to boost demand of methicillin resistant staphylococcus aureus testing systems in North America region. For instance, in July 2021, Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, announced the commercial launch of KIMYRSA (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market: Key Developments

On May 17, 2023, Roche Information Solutions India Pvt Ltd, a developing innovative solutions to help labs and clinicians, announced that it is showcasing innovative laboratory solutions and digital diagnostics through- "Innovation Past, Present and Future" at this year's WorldLab-EuroMedLab 2023 in Rome, Italy, 21-25 May. Attendees have the opportunity to experience first-hand Roche's latest technological advancements in lab automation, serum work area, molecular and point of care solutions.

In October 2020, 3M, is medical equipment company, expanded Surgical Portfolio with PREVENA RESTOR AXIO FORM Incision Management System is reduce edema, its help to remove infectious material, stabilize the incision, and reduce the time required for recovery.

In January 2020, Wockhardt is a global pharmaceutical and biotechnology company headquartered in Mumbai, India, announced regulatory approval of two novel antibiotics EMROK (IV) and EMROK O (Oral), for acute bacterial skin and skin structure infections, including diabetic foot infections and concurrent bacteraemia. The new drug target Methicillin resistant Staphylococcus aureus (MRSA), which is a leading cause of rising antimicrobial resistance (AMR).

In September 2021,  Laboratory Corporation of America, is a life sciences company based in the U.S., announced that it had entered into a definitive agreement to acquire select operating assets and intellectual property (IP) from Myriad Genetics, Inc. is genetic testing and precision medicine company based in United States, autoimmune business unit including the methicillin resistant staphylococcus aureus (MRSA) testing systems.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market: Key Trends

Rising demand for POC (point of care) diagnostics in MRSA

Rising demand for POC (point of care) diagnostics in MRSA is expected to drive the market growth. The technological developments in POC devices and test procedures that enable improved diagnosis is expected to drive the market growth. For instance, in October 2020, Exagen Diagnostics, a U.S.-based commercial-stage diagnostics company that develops and sells diagnostic tests, announced the launch of the second variant validated POC (point of care) diagnostics in MRSA to detect Staphylococcus Aureus infection, which has been found to be significantly elevated in patients with infection. These kinds of developments in the healthcare system and rising health expenditures, as well as increased knowledge of advanced Staphylococcus Aureus infection treatments are fueling the methicillin resistant staphylococcus aureus (MRSA) testing market in North America.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market: Restraint

Product Recall of Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems  

Product recall of methicillin resistant staphylococcus aureus (MRSA) testing systems is expected to hamper the growth of the global methicillin resistant staphylococcus aureus (MRSA) testing systems market over the forecast period. For instance, in June 2021, the U.S. FDA initiated a product recall on Becton Dickinson & Company is medical technology company that manufactures and sells medical devices, instrument systems, and reagents, BD Max MRSA test kit because the foil bags containing extraction tubes for BD MAX reagent products may not be sealed properly which lead to false representation of test results. An advisory has been released to all the users of BD Max instruments within testing facilities to ensure awareness and prevent false test results.

Key Players are focusing on quality, safety and efficacy of products.

Global Methicillin Resistant Staphylococcus Aureus (MRSA) Testing Systems Market - Key Players

Major players operating in the global methicillin resistant staphylococcus aureus (MRSA) testing systems market include Staphylococcus aureus (MRSA) testing systems market are F.Hoffmann-La Roche, Becton, Dickinson and Company, Hain Lifescience GmbH, BioMérieux, 3M Company, Bio-Rad Laboratories Inc., Abacus Diagnostica, Abbott Laboratories, Puritan Medical Products, Diatherix Eurofins, LLC, Arlington Scientific Inc., AdvanDx, Genspeed Biotech GmbH, Cepheid Inc., Luminex Corporation, and R-Biopharm AG.

*Definition: Methicillin-resistant staphylococcus aureus (MRSA) are different strains of Staphylococcus aureus, or ‘staph’ bacteria that are resistant to the antibiotic methicillin as well as to related beta-lactam antibiotics such as oxacillin, penicillin, amoxicillin, and cephalosporin. Methicillin-resistant Staphylococcus aureus (MRSA) testing is utilized to detect MRSAs and no other microbes. Nucleic acid amplification tests such as the polymerase chain reaction (PCR) can be used for direct detection of mecA, which is the most common gene mediating oxacillin resistance in staphylococci.